Hyperglycemia induced by pasireotide in patients with Cushing’s disease or acromegaly

Silverstein, Julie

doi:10.1007/s11102-016-0734-1

Cited by 67 publications

(47 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Soluble glucagon is now available for the treatment of diabetes and ready for trial in CHI. Pasireotide is licensed for adults with Cushing syndrome, where drug-related hyperglycaemia is noted as a side effect [49]. Alternative drug targets are also in the process of exploration.…”

Section: Future Therapeutic Optionsmentioning

confidence: 99%

“…Unlike octreotide, which exhibits greater selectivity for the SSR subtype 2, pasireotide is more selective for SSRA subtype 5 than 2. Pasireotide is licensed for adults with Cushing syndrome, where drug-related hyperglycaemia is noted as a side effect [49]. Pasireotide could be used for CHI, although concerns over hepatic impairment could be a limiting factor.…”

Section: Future Therapeutic Optionsmentioning

confidence: 99%

See 1 more Smart Citation

Therapies and outcomes of congenital hyperinsulinism‐induced hypoglycaemia

et al. 2018

View full text Add to dashboard Cite

Congenital hyperinsulinism is a rare disease, but is the most frequent cause of persistent and severe hypoglycaemia in early childhood. Hypoglycaemia caused by excessive and dysregulated insulin secretion (hyperinsulinism) from disordered pancreatic β cells can often lead to irreversible brain damage with lifelong neurodisability. Although congenital hyperinsulinism has a genetic cause in a significant proportion (40%) of children, often being the result of mutations in the genes encoding the KATP channel (ABCC8 and KCNJ11), not all children have severe and persistent forms of the disease. In approximately half of those without a genetic mutation, hyperinsulinism may resolve, although timescales are unpredictable. From a histopathology perspective, congenital hyperinsulinism is broadly grouped into diffuse and focal forms, with surgical lesionectomy being the preferred choice of treatment in the latter. In contrast, in diffuse congenital hyperinsulinism, medical treatment is the best option if conservative management is safe and effective. In such cases, children receiving treatment with drugs, such as diazoxide and octreotide, should be monitored for side effects and for signs of reduction in disease severity. If hypoglycaemia is not safely managed by medical therapy, subtotal pancreatectomy may be required; however, persistent hypoglycaemia may continue after surgery and diabetes is an inevitable consequence in later life. It is important to recognize the negative cognitive impact of early‐life hypoglycaemia which affects half of all children with congenital hyperinsulinism. Treatment options should be individualized to the child/young person with congenital hyperinsulinism, with full discussion regarding efficacy, side effects, outcomes and later life impact.

show abstract

Section: Future Therapeutic Optionsmentioning

confidence: 99%

Section: Future Therapeutic Optionsmentioning

confidence: 99%

Therapies and outcomes of congenital hyperinsulinism‐induced hypoglycaemia

et al. 2018

View full text Add to dashboard Cite

show abstract

“…[3][4][5][6] The hyperglycemia is attributed to reducing insulin secretion and incretin response. On the other hand, glucagon secretion and insulin sensitivity appear to be minimally affected.…”

Section: Discussionmentioning

confidence: 99%

“…3 In a phase 3 study Colao et al, 4 evaluated 358 patients with medically naive acromegaly. One year of monthly injections were compared between pasireotide LAR vs. Octreotide LAR.…”

Section: Introductionmentioning

confidence: 99%

Pasireotide-Induced Hyperglycemia

Kumar¹

2017

MOJCR

View full text Add to dashboard Cite

show abstract

“…The frequency of hyperglycaemia-related adverse events in patients with acromegaly treated with pasireotide varied between 57 and 67% (44,45).…”

Section: Efficacy Rates Of Srls Treatmentmentioning

confidence: 99%

MANAGEMENT OF ENDOCRINE DISEASE: Individualised management of acromegaly

Bollerslev

Heck

Olarescu

2019

European Journal of Endocrinology

View full text Add to dashboard Cite

Acromegaly is a rare and challenging disease calling for management in highly specialised multidisciplinary teams (MDTs). Untreated disease has severe morbidity and a clearly increased mortality. Major attainments have been gained over the latest decades, and therefore, the aim of this review is to discuss recent achievements in modern multimodal therapy of acromegaly performed by MDTs, with an emphasis on an individualised, proactive management from the time of diagnosis to long-term outcome. Treatment by surgery is the only potential curative treatment, however, even with modern techniques still with modest cure rates, leaving the patients to often long-term medical treatment. Treatment strategies have changed dramatically in the Western world over recent years, implying a more proactive treatment algorithm often with a shorter or longer pre-surgical treatment period with somatostatin receptor ligands (SRLs). Not all patients will however respond to primary treatment with conventional SRLs and there has recently been a development of potential biomarkers for response that has been implemented in the clinical routine. By today, multimodal treatment can bring every patient in remission, but still almost a third of all patients are undertreated according to large, international registries. On the other hand, it might be a challenge not to over treat thereby bringing the patient into a state of relative or absolute growth hormone deficiency. Clinical series published during the last decade on treatment of patients with acromegaly have indicated a normalisation of mortality, most probably reflecting the proactive and individualised modern treatment. In conclusion, modern, multimodal treatment seems to have normalised mortality, but still the patients suffer from a high multi-organ morbidity and often multipharmacy. Every patient should receive an individualised, proactive treatment in order to improve long-term outcome and to reduce costs for the society.Correspondence should be addressed to J Bollerslev . His special interest is within clinical and translational endocrinology, and in particular, in classical endocrine diseases, such as acromegaly and Cushing's, often studying bone as target tissues for clinical activity. A major topic has been clinical management of acromegaly, and especially searching for biomarkers for responsiveness to medical therapy. Prospectively collected data of newly diagnosed patients with acromegaly has been the background for current studies of individualised, multimodal and transdisciplinary treatment. European Journal of Endocrinology 181:2 R60 Review J Bollerslev and others Managing acromegaly https://eje.bioscientifica.com European Journal of Endocrinology 181:2 R61 Review J Bollerslev and others Managing acromegaly https://eje.bioscientifica.com European Journal of Endocrinology 181:2 R63 Review J Bollerslev and others Managing acromegaly https://eje.bioscientifica.com European Journal of Endocrinology 181:2 R64 Review J Bollerslev and others Managing acromegaly https://eje.bioscie...

show abstract

Hyperglycemia induced by pasireotide in patients with Cushing’s disease or acromegaly

Cited by 67 publications

References 38 publications

Therapies and outcomes of congenital hyperinsulinism‐induced hypoglycaemia

Therapies and outcomes of congenital hyperinsulinism‐induced hypoglycaemia

Pasireotide-Induced Hyperglycemia

MANAGEMENT OF ENDOCRINE DISEASE: Individualised management of acromegaly

Contact Info

Product

Resources

About